Search - tctmd.com

Displaying 361 - 380 of 389

Sort: Relevancy | Date

News Daily News

La Anticoagulación Reversible parece Prometedora en Pacientes con SCA sometidos a Cateterización

August 14, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

Presentation

Phase II Study Assessing the Efficacy, Safety of Variable Anticoagulation Reversal with REG1 in ACS

Presenter: 78830|Thomas Povsic

August 09, 2012

News Daily News

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Caitlin E. Cox

July 16, 2012

News Daily News

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Caitlin E. Cox

July 16, 2012

Presentation

Oral Anticoagulation Therapy in A-Fib Pts at High Bleeding Risk Undergoing Coronary Artery Stenting

Presenter: 204943|JM Ruiz-Nodar

July 13, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Daily News

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

June 01, 2012

Presentation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Presenter: Vivek Y. Reddy

May 30, 2012

News Daily News

HORIZONS-AMI: More Fallout When Stent Thrombosis Happens In-Hospital

May 09, 2012

News Daily News

High Prasugrel Reloading Dose Best for Suppressing Platelet Reactivity Prior to PCI

Jason Kahn

May 01, 2012

Presentation

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

Presenter: Robert G. Hart

April 27, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Conference News Cell Therapy 2012

Expedited Cell Therapy After STEMI Shows Promise

January 29, 2012

Presentation TCT 2012

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

Presenter: Thomas J. Povsic, John P. Vavalle, Laura H. Aberle, Steven L. Zelenkofske, Roxana Mehran, Mauricio G. Cohen, Christopher E. Buller, Jan H. Cornel, Jaroslaw D. Kasprzak, Gilles Montalescot, Peter Fail, Ian J. Sarembock, John H. Alexander

January 03, 2012

News Daily News

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

October 31, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

Advertisement

La Anticoagulación Reversible parece Prometedora en Pacientes con SCA sometidos a Cateterización

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Phase II Study Assessing the Efficacy, Safety of Variable Anticoagulation Reversal with REG1 in ACS

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Oral Anticoagulation Therapy in A-Fib Pts at High Bleeding Risk Undergoing Coronary Artery Stenting

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Rivaroxaban May be Cost-Effective for A-fib Patients

Watchman Works Just as Well Without Warfarin-Protected Transition

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

HORIZONS-AMI: More Fallout When Stent Thrombosis Happens In-Hospital

High Prasugrel Reloading Dose Best for Suppressing Platelet Reactivity Prior to PCI

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Expedited Cell Therapy After STEMI Shows Promise

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content